Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Biohaven Pharmaceutical has secured up to $250 million from Royalty Pharma to advance the development of zavegepant, a treatment for migraine and other indications. In exchange, Royalty Pharma will receive a 3% royalty on zavegepant sales and 0.4% on Nurtec ODT. The deal includes success-based milestone payments and a total of $200 million investment in commercial launch equity. The funding enhances Biohaven's CGRP receptor antagonist program, facilitating quicker expansion into new markets.
Royalty Pharma (RPRX) appointed Henry A. Fernandez and Ted W. Love, M.D. to its Board of Directors. Fernandez, CEO of MSCI, brings extensive finance expertise, while Love, CEO of Global Blood Therapeutics, contributes significant biopharma experience. This strategic enhancement follows their recent IPO, aimed at strengthening governance and business leadership. Fernandez will serve on the Audit Committee, and Love on the Nominating and Corporate Governance Committee, as Royalty Pharma continues to fund innovation within the biopharmaceutical sector.
Royalty Pharma (NASDAQ: RPRX) has scheduled its Q2 2020 financial results announcement for August 12, 2020, before U.S. markets open. The company will conduct a conference call at 8:00 AM ET on the same day, which will be available via webcast. Interested parties can join the live call by dialing the provided numbers and entering the passcode. Royalty Pharma is noted for its role in acquiring biopharmaceutical royalties and funding innovation within the industry, holding royalties from over 45 commercial products.
Royalty Pharma (Nasdaq: RPRX) has entered an agreement with PTC Therapeutics (Nasdaq: PTCT) to acquire a portion of the royalty interest in risdiplam for $650 million. Risdiplam, an oral therapy for spinal muscular atrophy (SMA), is under review by the FDA, with a PDUFA date set for August 24, 2020. This acquisition will minimally impact Royalty Pharma’s cash receipts and flow in 2020-2021 but is expected to enhance long-term growth. Royalty Pharma will acquire approximately 43% of the royalty, which ranges from 8% to 16% on worldwide risdiplam sales.
On June 25, 2020, New Ventures Funds announced the IPO of Royalty Pharma (NASDAQ:RPRX), raising $2.18 billion by selling 77,681,670 Class A shares at $28.00 per share. This marks the largest IPO of the year and the second largest in the pharmaceutical sector. With a portfolio of 45 marketed drugs and $18 billion in drug royalty transactions, Royalty Pharma aims to innovate within the biopharmaceutical ecosystem. New Ventures has invested in Royalty Pharma since 2006 and remains committed to supporting transformative healthcare investments.
Royalty Pharma plc (NASDAQ: RPRX) has successfully completed its initial public offering (IPO) of 89,333,920 Class A ordinary shares, priced at $28.00 each. The IPO size increased from an initial 70 million shares, reflecting strong demand. The company issued 71,652,250 shares, while selling shareholders contributed 17,681,670 shares. The offering included the full exercise of underwriters' options for an additional 11,652,250 shares. Trading began on June 16, 2020, on the Nasdaq Global Select Market under the symbol RPRX.